In addition to the other comment mentioning CAR-T therapies, we also have therapies based on tumor-infiltrating lymphocytes (TILs)

https://www.cancer.gov/news-events/cancer-currents-blog/2024...

https://jitc.bmj.com/content/8/2/e000848 (careful: Figure 1 can be very graphical, but it shows the huge positive impact of this therapy)

We also have therapies based on monoclonal recombinant antibodies conjugated with chemotherapeutics. Simply put, we can produce antibodies that are specific for markers present in the surface of cancer cells, and we can attach drugs that can kill those cells. The antibody part is what makes this type of therapy very effective (you target only cancer cells, and not healthy cells) and also very expensive.